Bluenosesol
Well-Known Member
- Messages
- 446
- Location
- Solihull, West Midlands
- Type of diabetes
- Type 2
- Treatment type
- Diet only
- Dislikes
- Dark mornings, intolerance any one with a superiority complex...
Folks,
whilst mooching on the Net, I came across a new drug referred to as Eucreas. Apparently its a combination of Metformin and Vildagliptin and as a combo, they are supposed to achieve a 1.1 mmol reduction in HBA1C as opposed to taking Metformin alone.
If its in common use, I would like to ask my DN about it.
WIKI states ..
Vildagliptin (previously identified as LAF237, trade name Galvus) is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1[2][3] and GIP[3] by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.[2]
Apparently approved in EU but not in US.
Regards Steve.
whilst mooching on the Net, I came across a new drug referred to as Eucreas. Apparently its a combination of Metformin and Vildagliptin and as a combo, they are supposed to achieve a 1.1 mmol reduction in HBA1C as opposed to taking Metformin alone.
If its in common use, I would like to ask my DN about it.
WIKI states ..
Vildagliptin (previously identified as LAF237, trade name Galvus) is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1[2][3] and GIP[3] by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.[2]
Apparently approved in EU but not in US.
Regards Steve.